DENVER, CO--(Marketwired - October 01, 2013) - American Eagle Energy Corporation (OTCQX: AMZG) announced that it has amended its Senior Credit Facility with Morgan Stanley Capital Group Inc. to reduce its working capital requirement from $33.0 million to $23.5 million as a condition precedent to obtaining an additional $40 million earmarked for the purpose of purchasing additional interests in the Spyglass Project area in the Williston Basin in northwestern Divide County, North Dakota from a joint partner.

ABOUT AMERICAN EAGLE ENERGY CORPORATION

American Eagle Energy Corporation is an independent exploration and production operator that is focused on acquiring acreage and developing wells in the Williston Basin of North Dakota, targeting the Bakken and Three Forks shale oil formations. The Company is based in Denver, CO. More information about American Eagle can be found at www.americaneagleenergy.com or by contacting investor relations at 303-798-5235 or ir@amzgcorp.com. Company filings with the Securities and Exchange Commission can be obtained free of charge at the SEC's internet site at www.sec.gov.

SAFE HARBOR

This press release may contain forward-looking statements regarding future events, including the purchase of additional interests in the Spyglass Project, that are subject to the safe harbors created under the Securities Act of 1933 (the "Securities Act") and the Securities Exchange Act of 1934 (the "Exchange Act"). All statements other than statements of historical facts included in this press release regarding the Company's financial position, business strategy, plans and objectives of management for future operations, industry conditions, and indebtedness covenant compliance are forward-looking statements. When used in this report, forward-looking statements are generally accompanied by terms or phrases such as "estimate," "project," "predict," "believe," "expect," "anticipate," "possible," "target," "plan," "intend," "seek," "goal," "will," "should," "may" or other words and similar expressions that convey the uncertainty of future events or outcomes. Items contemplating or making assumptions about, actual or potential future sales, market size, collaborations, and trends or operating results also constitute such forward-looking statements. 

Forward-looking statements involve inherent risks and uncertainties and important factors (many of which are beyond the Company's control) that could cause actual results to differ materially from those set forth in the forward-looking statements, including the following: general economic or industry conditions, nationally and/or in the communities in which the Company conducts business, changes in the interest rate environment, legislation or regulatory requirements, conditions of the securities markets, our ability to raise capital, changes in accounting principles, policies, or guidelines, financial or political instability, acts of war or terrorism, other economic, competitive, governmental, regulatory and technical factors affecting the Company's operations, products, services, and prices. 

The Company has based these forward-looking statements on its current expectations and assumptions about future events. While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other risks, contingencies, and uncertainties, most of which are difficult to predict and many of which are beyond the Company's control. The Company does not assume any obligations to update any of these forward-looking statements.

INVESTOR RELATIONS CONTACT: Marty Beskow Vice President of Capital Markets and Strategy American Eagle Energy Corporation 303-798-5235 ir@amzgcorp.com www.americaneagleenergy.comBrad Holmes EnergyIR 713-654-4009 B_holmes@att.net

Grafico Azioni Immage Biotherapeutics (CE) (USOTC:IMMG)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Immage Biotherapeutics (CE)
Grafico Azioni Immage Biotherapeutics (CE) (USOTC:IMMG)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Immage Biotherapeutics (CE)